Global Health Ventures Receives the First Shipment of Its Commercially Manufactured Male Enhancement Drug "X-Excite"

The Company plans to meet the regulatory bodies in the United States, Canada and Europe to assess the time and length of the human clinical trials in the near future. The X-Excite drug is the Company's lead prescription drug. The Company is hoping to manufacture it so it can be qualified under the OTC (over the counter for pharmaceuticals) Market. If approvals are attained we believe that the product will generate a very lucrative revenue stream for Global Health.

Our lead life-style pharmaceutical product, (X-Excite), is a male sexual enhancement drug. X-Excite is a new formulation of an existing sexual enhancement drug, which is designed to rapidly enter the blood system, maximizing its efficacy and performance. The drug is developed to work sublingually, thus having a more rapid mode of action, and bypassing all the inconveniences and many side effects associated with other application routs. Life style products, such as Viagra(TM), Cialis(TM) and Levitra(TM), etc are highly lucrative, (nearly $5 billion) products for pharmaceutical companies. This lucrative market will continue to grow for the foreseeable future. The arrival of our new drug (X-Excite) with its fewer side effects and the rapid mode of action meets and will exceed the markets needs. The Company believes it will be able to take a lion's share of the market thus generating significant revenue for the Company.

"We are pleased that we have completed the research on this product and the manufacturing seems not to be a difficult or expensive process. With the recent successful fund raising, the Company should be able to push the approval of this product through regulatory doors". Said Dr. Salari, President and CEO.

About Global Health Ventures, Inc.

Global Health Ventures, Inc. (the "Company") is a specialty pharma with focus on the Over-The-Counter drug market. The Company has a new proprietary platform technology that delivers many approved drugs via the sublingual (under the tongue) route. This unique method delivers low dose drugs directly to the blood stream, bypassing all the side effects of digestive and liver system breakdowns, while maintaining product efficacy. The Company currently has five products in late stage development and several more underway.

Safe Harbor Statement

This press release includes forward-looking statements that involve a number of risks and uncertainties, including the success of the products in commercializing and developing. Further, the risks involve the ability of the Company to raise capital to fund its operations and the capital requirements for the development and marketing of its products. Investors are encouraged to review the risk factors listed or described from time to time in the Company's filings (10K) with the Securities and Exchange Commission.